Mainz Biomed Partners with Quest Diagnostics to Commercialize its Colorectal Cancer Screening Test
Shots:
- Mainz Biomed has signed an agreement with Quest Diagnostics for the commercialization of its next-gen. screening test, ColoAlert, for colorectal cancer
- Quest will offer lab services for Mainz Biomed's ReconAAsense study, assessing efficacy of the test among ~15,000 subjects across the US, in exchange for an option of semi-exclusive rights to provide testing services using test kit for 18mos., post-FDA approval
- Mainz Biomed's stool-based ColoAlert test leverages PCR technology to identify tumor DNA & genetic mutations for early CRC detection. Preliminary data has depicted favorable sensitivity & specificity, incl. for advanced adenomas
Ref: Mainz Biomed | Image: Mainz Biomed & Quest Diagnostics
Related News:- Mainz Biomed and TomaLab Collaborate to Enhance the Diagnosis of Colorectal Cancer Using ColoAlert
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
